Anti-PD-1 antibodies
US11008391B2 · kind B2 · utility
2Cited by
40References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2016 |
| Grant date | May 18, 2021 |
| Priority date | — |
| Expiry date | Dec 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.